Drug intelligence / Profile preview

CombiflexOmega peri

Development stage: Phase 3
Lead developer: B. Braun
Administration: Intravenous

Overview

CombiflexOmega peri appears to be a parenteral nutrition solution intended for peripheral infusion. It likely contains a combination of amino acids, lipids (including omega fatty acids), glucose, and electrolytes for patients with moderately increased, basal or low nutritional requirements when oral or enteral nutrition is impossible, insufficient or contraindicated. The product is designed for intravenous administration through peripheral veins.

Brand names: CombiflexOmega peri
Other names: Combiflex Omega Peripheral

Beyond the preview

Go deeper on CombiflexOmega peri.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CombiflexOmega peri.

Explore the full profile